1. Scrip
  2. >>New Products

Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

 
• By Sten Stovall

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.

Samples
AZ And Merck Seek Lynparza Use Across Multiple Tumor Settings • Source: Shutterstock

Commercial prospects for the six-month-old global collaboration between AstraZeneca PLC and Merck & Co. Inc. to jointly develop and commercialize AZ's Lynparza (olaparib) got a big boost Jan. 12 when the FDA expanded use of the PARP inhibitor to include treatment of patients with metastatic breast cancer who have a mutated BRCA gene, the first such regulatory approval globally.

The okay was based on data from the randomized, open-label, Phase III OlympiAD trial which found olaparib monotherapy had a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Big Top-Level Shifts At Sun: Ganorkar Is MD, Ex-Takeda Exec To Helm US Business

 
• By Anju Ghangurde

Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.